According to the Report, the Size of Asia Pacific Injectable Drug Delivery Market is valued at USD 10437.4 million in 2019 and estimated to be growing at a CAGR of 12.15%, to reach 18794.1 million by 2024 during the forecast period 2019-2024.
Injectable drug delivery is characterized as the introduction of a drug or drugs in the patient by utilizing a delivery device. Injectables permit the transport of drug in fluid form, directly into the body.
The key factors driving the development of injectables are an increase in the cases of cancer and diabetic patients, enhanced patient consistence to drug delivery systems and advancement in technology. The key limiting factors that affect the development of the injectables market incorporate injuries caused while administering injectables, patient safety issues, the advancement of substitute drug delivery methods and product reviews.
The developing Asian and Latin America nations collectively represent the fastest developing business sector for injectables because of the increase in occurrences of disease and diabetes in patients and furthermore their consistency to novel advancements. Besides, the drug and device manufacturers are concentrating on the major rising injectables market of Asia and Asia-Pacific because of less stringent directions for obtaining approvals on less competition and devices.
Asia Pacific Injectable Drug Delivery Market has been segmented and sub-segmented into the following categories:
Top Companies leading the Asia Pacific Injectable drug delivery market profiled In the report are Antares Pharmaceuticals Ltd, Baxter International, Becton Dickinson Company, Elcam Medical, Eli Lily and Company, Unilife Corporation and West Pharmaceutical Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Device Type
5.1.1 Introduction
5.1.2 Self-injection Devices
5.1.3 Conventional Devices
5.1.4 Y-o-Y Growth Analysis, By Device Type
5.1.5 Market Attractiveness Analysis, By Device Type
5.1.6 Market Share Analysis, By Device Type
5.2 Formulation
5.2.1 Introduction
5.2.2 Conventional Drug Delivery
5.2.3 Novel Drug Delivery
5.2.4 Y-o-Y Growth Analysis, By Formulation
5.2.5 Market Attractiveness Analysis, By Formulation
5.2.6 Market Share Analysis, By Formulation
5.3 Therapeutic Use
5.3.1 Introduction
5.3.2 Autoimmune Disorders
5.3.3 Hormonal Disorders
5.3.4 Oncology
5.3.5 Y-o-Y Growth Analysis, By Therapeutic Use
5.3.6 Market Attractiveness Analysis, By Therapeutic Use
5.3.7 Market Share Analysis, By Therapeutic Use
5.4 End-user
5.4.1 Introduction
5.4.2 Hospitals
5.4.3 Homecare Settings
5.4.4 Research Institutes
5.4.5 Clinical Laboratories
5.4.6 Other
5.4.7 Y-o-Y Growth Analysis, By End-user
5.4.8 Market Attractiveness Analysis, By End-user
5.4.9 Market Share Analysis, By End-user
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Device Type
6.1.3.3 By Formulation
6.1.3.4 By Therapeutic Use
6.1.3.5 By End-user
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Device Type
6.1.4.3 By Formulation
6.1.4.4 By Therapeutic Use
6.1.4.5 By End-user
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Device Type
6.1.5.3 By Formulation
6.1.5.4 By Therapeutic Use
6.1.5.5 By End-user
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Alkermes Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Bend Research
8.3 BIND Biosciences Inc.
8.4 Endocyte
8.5 Genentech Inc.
8.6 MicroCHIPS Inc.
8.7 Pearl Therapeutics Inc.
8.8 Polymer Factory
8.9 Presage Bioscience
8.10 QLT Inc.
8.11 UCB Group.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
